Experienced in Gliosarcoma

Dr. Pavani Chalasani

Hematology Oncology | Hematology | Oncology
Medical Faculty Associates, Inc
2150 Pennsylvania Ave Nw, 
Washington, DC 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Experienced in Gliosarcoma
Medical Faculty Associates, Inc
2150 Pennsylvania Ave Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Pavani Chalasani is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Chalasani is rated as an Experienced provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast. Dr. Chalasani is currently accepting new patients.

Her clinical research consists of co-authoring 53 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in AZ
Hospital Affiliations
George Washington Univ Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

MEDICAL FACULTY ASSOCIATES, INC
2150 Pennsylvania Ave Nw, Washington, DC 20037

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Enrollment Status: Recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Fulvestrant, Adjuvant Therapy
Study Phase: Phase 2
Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
Enrollment Status: Recruiting
Publish Date: March 01, 2024
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Olaparib
Study Phase: Phase 2
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological
Study Drug: CAB-AXL-ADC
Study Phase: Phase 1/Phase 2
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2025
Intervention Type: Biological
Study Drug: Sacituzumab Govitecan
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Tamoxifen, Prophylactic Loperamide
Study Phase: Phase 2
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
Enrollment Status: Completed
Publish Date: January 15, 2025
Intervention Type: Biological
Study Drug: CAB-ROR2-ADC
Study Phase: Phase 1/Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Single Arm Phase II Study to Evaluate Efficacy of T-DM1 With Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer
A Single Arm Phase II Study to Evaluate Efficacy of T-DM1 With Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer
Enrollment Status: Completed
Publish Date: August 13, 2024
Intervention Type: Drug
Study Drugs: Palbociclib, T-DM1
Study Phase: Phase 2
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Phase IB/II Open-label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor Positive and HER2-positive Metastatic Breast Cancer
Phase IB/II Open-label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor Positive and HER2-positive Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Tucatinib with Palbociclib and Letrozole
Study Phase: Phase 1/Phase 2
Pilot Trial to Evaluate Blood and Imaging Based Biomarkers for Aromatase Inhibitor Induced Musculoskeletal Syndrome
Pilot Trial to Evaluate Blood and Imaging Based Biomarkers for Aromatase Inhibitor Induced Musculoskeletal Syndrome
Enrollment Status: Completed
Publish Date: August 24, 2023
Intervention Type: Diagnostic test
Study Phase: Not Applicable
NSAID Effects on Clinical and Imaging Breast Biomarkers
NSAID Effects on Clinical and Imaging Breast Biomarkers
Enrollment Status: Completed
Publish Date: February 10, 2023
Intervention Type: Drug
Study Drug: Sulindac
Study Phase: Phase 2
A Study to Investigate Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced Alopecia
A Study to Investigate Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced Alopecia
Enrollment Status: Completed
Publish Date: December 16, 2022
Intervention Type: Drug
Study Drug: Keratinocyte growth factor
Study Phase: Early Phase 1
Title A Pilot Trial to Evaluate Syndros in Decreasing Opioid Requirement in Patients With Bone Metastases From Breast Cancer
Title A Pilot Trial to Evaluate Syndros in Decreasing Opioid Requirement in Patients With Bone Metastases From Breast Cancer
Enrollment Status: Completed
Publish Date: April 29, 2021
Intervention Type: Drug
Study Phase: Early Phase 1
Evaluating the Role of Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer
Evaluating the Role of Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer
Enrollment Status: Completed
Publish Date: November 19, 2020
Intervention Type: Procedure, Other
Study Phase: Not Applicable
Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)
Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)
Enrollment Status: Completed
Publish Date: July 23, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 21 Less Clinical Trials

53 Total Publications

Profiles of quality of life among US young adult cancer survivors and their associations with potential psychosocial intervention targets of hope and psychological flexibility.
Profiles of quality of life among US young adult cancer survivors and their associations with potential psychosocial intervention targets of hope and psychological flexibility.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: June 10, 2025
Similar Doctors
Distinguished in Gliosarcoma
Dr. Daya S. Sharma
Oncology | Hematology Oncology | Hematology
Distinguished in Gliosarcoma
Dr. Daya S. Sharma
Oncology | Hematology Oncology | Hematology

American Oncology Partners PA

19520 Doctors Dr, 
Germantown, MD 
 (22.3 miles away)
240-912-7645
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Daya Sharma is an Oncologist and a Hematologist Oncology provider in Germantown, Maryland. Dr. Sharma is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Astrocytoma, Gliosarcoma, Embryonal Tumor with Multilayered Rosettes, and Neuroepithelioma. Dr. Sharma is currently accepting new patients.

Advanced in Gliosarcoma
Dr. Behzad Doratotaj
Hematology Oncology | Hematology | Oncology
Advanced in Gliosarcoma
Dr. Behzad Doratotaj
Hematology Oncology | Hematology | Oncology

Medstar Medical Group Ii LLC

18101 Prince Philip Dr, 
Olney, MD 
 (17.5 miles away)
301-570-7404
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Behzad Doratotaj is a Hematologist Oncology specialist and a Hematologist in Olney, Maryland. Dr. Doratotaj is rated as an Advanced provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Astrocytoma, Oligodendroglioma, Ependymoma, and Embryonal Tumor with Multilayered Rosettes. Dr. Doratotaj is currently accepting new patients.

Advanced in Gliosarcoma
Dr. Mark G. Goldstein
Hematology Oncology | Oncology | Hematology
Advanced in Gliosarcoma
Dr. Mark G. Goldstein
Hematology Oncology | Oncology | Hematology

American Oncology Partners PA

6410 Rockledge Dr, Suite 660, 
Bethesda, MD 
 (9.6 miles away)
301-571-0019
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Goldstein is a Hematologist Oncology specialist and an Oncologist in Bethesda, Maryland. Dr. Goldstein is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Childhood Iron Deficiency Anemia, Anal Cancer, Myelodysplastic Syndrome (MDS), and Pleuropulmonary Blastoma. Dr. Goldstein is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chalasani's expertise for a condition
ConditionClose
View All 96 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile